Cite
HARVARD Citation
Schuler, M. et al. (n.d.). First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials. European journal of cancer. pp. S176-S177. [Online].